Palliative treatment with self-expanding metal stents (SEMS) is regarded as a safe and highly effective procedure for relief of symptoms caused by malignant obstructions of the gastrointestinal (GI) tract \[[@CR1]--[@CR8]\]. Most studies concerning treatment with SEMS, whether randomized, comparative, or merely descriptive, focus on technical success (e.g., correct deployment of the stent), clinical success (restored passage), procedure-related complications, and cost-effectiveness. Typically, the clinical outcomes of SEMS treatment have been evaluated by the physician \[[@CR9]\]; only a few prospective studies reported repeated symptom assessments by the patient \[[@CR10]--[@CR16]\]. Since patients' and physicians' ratings of treatment effects do not always correspond well, palliative treatment efforts such as SEMS for malignant GI obstructions should be evaluated by individual outcome measures reported by the patients as well as by the physicians \[[@CR17]--[@CR22]\].

The main objective of this multicenter study was to use patient-reported outcomes to evaluate the treatment effects of SEMS on quality of life (QoL) and symptoms related to malignant GI and biliary obstruction. An additional aim of the study was to compare patient- and physician-reported evaluations of the treatment's effects.

Materials and methods {#Sec1}
=====================

Nine Norwegian hospitals performing SEMS treatment for GI obstructions participated in the present study. The inclusion period was from November 2006 to April 2008. Patients were eligible for consecutive inclusion according to the following criteria: (1) symptoms related to malignant GI obstruction, (2) indication for treatment with all types of metal stents established, (3) fluency in oral and written Norwegian, and (4) cognitive capability to complete the questionnaires. Patients who received their colonic stent as a "bridge to surgery" (i.e., to relieve the acute obstruction prior to elective surgery) and underwent bowel resection within 2 weeks after stent placement were not asked to complete the questionnaire after 2 weeks and were thus not included in the analyses. The study was approved by the Regional Committee for Medical Research Ethics in Southern Norway and the Data Protection Supervisor at Oslo University Hospital, Ullevål. All patients received oral and written information about the study. Written informed consent was obtained from all participants.

Stent procedure {#Sec2}
---------------

All stents were deployed endoscopically under fluoroscopic guidance. Both covered and uncovered stents were used for esophageal and biliary stent treatment, while uncovered stents were used in other locations.

Assessment of patient-reported outcomes {#Sec3}
---------------------------------------

The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire, EORTC QLQ-C30, version 3.0 \[[@CR23]\], was used to assess patient-reported outcomes, supplemented with selected questions from other relevant EORTC organ- and disease-specific modules (<http://www.eortc.be/>). The EORTC QLQ-C30 is a cancer-specific 30-item self-reporting questionnaire consisting of both multi-item scales and single-item measures. These include five functional scales (i.e., physical, role, cognitive, emotional, and social), three symptom scales (i.e., fatigue, nausea/vomiting, and pain), and six single items (i.e., dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial problems), as well as two questions where the patients assessed their overall health and QoL on a scale from 1 to 7. Combining these two scores resulted in a global health score.

EORTC recommends that organ-specific modules be used in addition to the core questionnaire to capture diagnosis- or treatment-specific problems. For the purpose of the present study, a selection of questions was made from the relevant organ-specific modules to reduce the respondent's burden and to focus on specific problems pertaining to the different diagnostic or stent groups. Questions to be answered by the patients receiving esophageal, biliary, and colonic stents were selected from the stomach module EORTC QLQ-STO22 \[[@CR24]\], the pancreatic module EORTC QLQ-PAN26 \[[@CR25]\], and the colorectal module EORTC QLQ-CR38 \[[@CR26]\], respectively (Table [2](#Tab2){ref-type="table"}). Patients who received gastroduodenal stents did not answer any additional questions as their main obstruction-related symptoms, nausea and vomiting, were specifically addressed by the core questionnaire.

Higher scores on the symptom scales and single items from the core questionnaires and the organ-specific modules indicated more severe symptoms, while higher scores on the functional scales indicate better functioning. All items were to be answered on an ordinal scale ranging from 1 ("Not at all") to 4 ("Very much"), except for the two modified visual analog scales assessing global health and QoL; they ranged from 1 to 7. The time frame was the past 7 days. Scale and item scores were transformed into a continuous scale from 0 to 100, as described in the EORTC Scoring Manual \[[@CR27]\]. A mean score difference of 5--10 is usually regarded as a small but clinically noticeable change for the patients, a change between 10--20 as moderate, and \>20 as a large clinical change \[[@CR28], [@CR29]\].

Administration of questionnaires {#Sec4}
--------------------------------

All assessments were performed twice, at inclusion (−2 to +1 day before/after the procedure) and 2 weeks after treatment. The questionnaire was administered to the study participants upon admission by the treating physician or a study nurse. The same questionnaire was given to the patients when leaving the hospital. The patients were instructed to complete the second questionnaire 2 weeks after stent treatment and return it by mail. The 2-week time span between assessments was chosen to reach the maximum effect of the stent treatment and reduce the impact of disease progression. To reduce the influence of recall bias, the patients had to complete the initial questionnaire no later than the day after the procedure and the second questionnaire no later than 3 weeks after treatment. The physicians assessed the same organ-specific symptoms at inclusion and the second assessment at hospital discharge or 2 weeks after stent treatment if the patient was still hospitalized. The same physician was responsible for the before and after assessment of symptoms.

Statistical analysis {#Sec5}
--------------------

Power calculations were based on a mean change of 10 with a standard deviation (SD) of 15 of global health, with 90% power and a 5% level of significance, which yielded a sample size of 26 patients in each of the treatment groups for the four stent locations. Wilcoxon signed-rank test with 5% significance level was used when evaluating changes of symptoms before and after treatment. Statistical analyses were performed using SPSS 16.0 (SPSS, Inc., Chicago, IL).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A total of 273 patients were eligible for inclusion in the study, varying from 2 to 105 patients at the nine participating centers. Two hundred thirty-eight (87%) patients completed the questionnaire prior to the stent procedure, and 162 (68%) of these completed both questionnaires. Twenty-seven patients did not return the second form for unknown reasons (Fig. [1](#Fig1){ref-type="fig"}). Ninety-nine males and 63 females with a median age of 72 years were included. Clinical and demographic characteristics are given in Table [1](#Tab1){ref-type="table"}. The most frequent diagnoses were cancer of the colon and pancreas. Of the 18 patients with gastric cancer who received stents, eight had obstructions located in the cardia ventriculi and were treated with esophageal stents. Ten patients had gastric outlet obstruction and were treated with duodenal stents.Fig. 1Flowchart showing the selection of the 162 patients included in this studyTable 1Clinical and demographic characteristics of 162 patients treated by self-expanding metal stents for malignant gastrointestinal obstructionAge \[median (range)\]72 (33--93)Gender M/F99/63Survival \[median (range)\] (days)111 (15--535)Diagnoses Colon cancer49 (30%) Pancreatic cancer41 (25%) Gastric cancer18 (11%) Esophageal cancer28 (17%) Bile duct cancer9 (6%) Other malignancies^a^17 (11%)Other palliative treatment Chemotherapy (during day 0--14)18 (11%) Radiotherapy (during day 0--14)7 (4%)Stent locations Esophageal41 (25%) Gastroduodenal33 (20%) Biliary40 (25%) Colon48 (30%)^**a**^Breast cancer, *n* = 1, lymphoma, *n* = 1; lung cancer, *n* = 3; prostate cancer, *n* = 2; hepatocellular carcinoma, *n* = 1; gallbladder cancer, *n* = 1; thyroid cancer, *n* = 1; papillary cancer, *n* = 1; ovarian cancer, *n* = 3; duodenal cancer, *n* = 1; malignant melanoma, *n* = 2

Patient-reported outcomes {#Sec8}
-------------------------

Patients reported a clinically and statistically significant reduction in all obstruction-related symptoms in all four stent locations, with a mean reduction of at least 20 (*P* \< 0.02). Furthermore, a clinically and statistically significant improvement in global health function (*P* \< 0.03) was observed in all treatment groups. Additionally, various other symptoms improved significantly: nausea/vomiting (colon and biliary), appetite loss (biliary and gastroduodenal), pain (gastroduodenal and colonic), and constipation (colonic) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}). The total numbers of patients experiencing symptomatic improvement ≥ 20, improvement \< 20, or worsening are reported in Table [6](#Tab6){ref-type="table"}.Table 2Scores from EORTC C30^a^ and selected obstruction-related questions from EORTC OES 18 given by 41 patients treated with esophageal stentsBeforeAfterDifference*P* valueGlobal health function^b^30.0 (18.0)39.1 (26.1)9.2 (26.4)0.03Symptom scales^a,c^ Nausea/vomiting37.8 (31.0)33.7 (31.7)4.1 (39.6)0.49 Pain43.5 (29.6)51.2 (31.5)−7.7 (34.6)0.20Single items^c^ Appetite loss69.1 (38.3)61.8 (39.1)7.3 (41.8)0.31Organ-specific questions from EORTC OES 18^c^ Have you had problems eating solid food?86.8 (26.3)51.0 (40.1)36.0 (51.6)\<0.001 Have you had problems eating liquidized or soft food?63.1 (35.3)30.0 (37.3)32.4 (52.3)0.001 Have you had problems drinking liquids?38.6 (36.8)16.7 (26.5)22.0 (41.2)0.002All values are mean (SD)^a^A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores^b^Scale from 0 to 100; high scores represent higher level of functioning^c^Scale from 0 to 100; high scores represent more severe symptomsTable 3EORTC C30^a^ results from 33 patients treated with gastroduodenal stentsBeforeAfterDifference*P* valueGlobal health function^b^22.0 (19.3)38.4 (26.4)16.4 (24.8)\<0.001Symptom scales^b^ Pain57.6 (28.6)39.9 (36.3)17.7 (36.3)0.014 Nausea/vomiting63.1 (31.1)30.3 (27.5)32.8 (38.7)\<0.001Single items^b^ Appetite loss^c^81.8 (25.1)65.7 (37.7)16.2 (34.5)0.013All values are mean (SD)^a^A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores^b^Scale from 0 to 100; high scores represent more severe symptoms^c^Scale from 0 to 100; high scores represent higher level of overall functioningTable 4Scores from EORTC C30^a^ and selected obstruction-related questions from EORTC PAN26 from 40 patients treated with biliary stentsBeforeAfterDifference*P* valueGlobal health function^b^30.4 (25.9)48.3 (28.0)17.9 (34.3)0.003Symptom scales^c^ Pain48.3 (36.2)28.8 (25.0)19.6 (31.8)0.001 Nausea/vomiting35.0 (30.8)21.3 (23.3)13.8 (28.7)0.005Single items^c^ Appetite loss61.7 (41.0)45.8 (41.8)15.8 (32.0)0.007Organ-specific questions from EORTC PAN 26^c^ Have you been itching?46.6 (39.1)23.3 (32.2)23.3 (51.3)0.01All values are mean (SD)^a^A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores^b^Scale from 0 to 100; high scores represent higher level of overall functioning^c^Scale from 0 to 100; high scores represent more severeTable 5Scores from EORTC C30^a^ and selected questions from EORTC CR38 from 46 patients treated with colon stentsBeforeAfterDifference*P* valueGlobal health function^b^38.0 (24.8)48.7 (23.7)10.7 (24.5)0.009Symptom scales^a,\ c^ Pain49.3 (33.9)28.4 (30.0)20.9 (39.0)0.001 Nausea /vomiting29.4 (34.1)13.8 (21.5)15.6 (33.6)0.003Single items^c^ Appetite loss45.4 (40.8)31.9 (35.4)13.5 (45.4)0.04 Constipation53.9 (43.7)24.8 (32.2)29.1 (46.0)\<0.001 Diarrhea37.6 (37.2)45.4 (33.6)−7.8 (45.7)0.26Organ-specific questions from EORTC CR38^c^ Have you had abdominal pain?53.6 (38.2)32.6 (28.5)21.0 (37.4)\<0.001 Have you felt bloated?67.4 (36.2)27.5 (30.0)40.0 (44.8)\<0.001All values are mean (SD)^a^A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores^b^Scale from 0 to 100; high scores represent higher level of overall functioning^c^Scale from 0 to 100; high scores represent more severe symptomsTable 6Patient-reported symptomatic effect of stent treatmentNumber of patients with clinical effect on ≥1 symptomsNumber of patients with no effect or worsening of symptomsEsophageal stent34 (81%)8 (19%)Gastroduodenal stent16 (48%)17 (52%)Biliary stent20 (50%)20 (50%)Colonic stent33 (69%)15 (31%)

The scorings from patients who completed the pretreatment questionnaire before treatment were similar to those from patients who completed it the day after treatment. Sixty-four patients (40%) completed the first assessment the day after stent insertion because of emergency stent treatment or pronounced symptoms before treatment. The rate of missing items was low, 0.9 and 1.0% in the two assessments, respectively. For the multi-items scales, missing values were assigned according to a standard scoring procedure (EORTCs scoring manual, \[[@CR27]\]) by replacing missing items with the scale mean values, provided that half or more of the scale items were completed.

Comparison of symptoms evaluated by patients and physicians {#Sec9}
-----------------------------------------------------------

When comparing the patients' and physicians' scores, a significant difference in the answers of six of seven questions before treatment was found, whereby the physicians indicated symptoms as more pronounced than the patients (*P* \< 0.02). However, when comparing the post-treatment evaluation, the scores tended to be similar (a statistically significant difference was found for two questions, see Table [7](#Tab7){ref-type="table"}). When evaluating the clinical effect as an improvement in obstructive symptoms, the physicians reported a larger mean reduction in obstructive symptoms and, thus, a better treatment effect as compared to the patients.Table 7Comparison of scoring by patients and physicians before and after stent treatmentSymptom score before stent treatmentSymptom score after stent treatmentChange in symptom scoreStent locationPatientPhysician*P* value diff.PatientPhysician*P* value diff.Patient diff. before/afterPhysician diff. before/after*P* value diff.Esophagus Have you had problems eating solid food?87930.1351580.4437340.78 Have you had problems eating liquidized or soft food?63820.00230330.4933490.22 Have you had problems drinking liquids?39640.00117140.6325500.001Stomach/duodenum Have you vomited?63830.00230190.2432650.007Biliary tree Have you been itching?47600.01523260.3824340.24Colon Have you had abdominal pain?5470\<0.0013312\<0.0012158\<0.001 Have you felt bloated?67780.00228150.0340640.007All values are mean. Scale from 0 to 100; high scores represent more severe symptoms

The median hospital stay was 4 days (range = 0--64). Therefore, physicians completed their second symptom assessment \<7 days after the first registration in (131/162) 81% of the cases. The patients completed their second assessment of symptoms after 2 weeks (assessing symptoms between days 7 and 14).

Short-term outcome/complications {#Sec10}
--------------------------------

During the first week, 12 of 162 patients (7%) experienced complications: three nonfunctional stents, two stent migrations, two bleeding episodes, two episodes of cholangitis, one tracheal-esophageal fistula, one stent obstruction by food impaction, and one stent obstruction by tumor overgrowth. There was no procedure-related mortality.

Discussion {#Sec11}
==========

This study is one of very few that evaluates the symptomatic effect of palliative GI stenting based on patient-reported outcomes. Furthermore, to our knowledge it is the first to compare patients' and physicians' assessments of the symptomatic effect of SEMS treatment. The present study demonstrates that the majority of patients found treatment with SEMS effective in relieving obstructive symptoms in all GI tract locations. Additionally, patients reported a significant clinical improvement in global health after 2 weeks for all four stent locations. The physicians tended to evaluate pretreatment symptoms as more severe than did the patients. The postprocedure scorings were more similar.

This study shows that treatment with SEMS is effective in relieving symptoms related to malignant GI obstruction. Our conclusion is strengthened by the fact that patients in this study were treated at small local centers, not large expert centers. SEMS as palliative principle seems to be effective independent of location. With regard to the symptomatic effect on esophageal and gastric outlet obstructions, our findings are in accordance with previous studies. Additionally, were we able to find significantly improved general well-being and better QoL, which most previous studies had not been able to document \[[@CR10], [@CR12]\]. A study of colon obstruction using patient-reported outcomes ended early and was therefore not able to make a conclusion \[[@CR30]\].

That physicians' and patients' perceptions of symptoms differ is in line with previous studies in palliative medicine that compared physicians and patients, although underestimation of patients' symptoms by physicians is more common \[[@CR17]--[@CR21]\]. We do not know the reasons for the discrepancies in scoring found in our study; but one plausible explanation may reflect the enthusiasm of the physicians performing these procedures and their needs to justify the indication. The study was not designed to clarify this question.

The physicians completed the second questionnaire earlier than the patients (earlier than day 7 for 81% of the patients). The study protocol did not include a scheduled follow-up after stent treatment. The patients were often severely ill, with long travelling distance to hospital, and an extra hospital visit to allow the physician to perform a symptom assessment was hence not included in the follow-up. As the hospital stay related to the stent procedure usually was of short duration, the physicians' scoring often had to be performed at discharge from hospital. However, it is likely that the questionnaire's 1-week time format reduced the influence of the discrepancy of when the physicians and patients did the second assessment.

Although there were significant improvements for the group in total, there was interindividual variation and some patients did not experience improvement in their obstructive symptoms. A review of the medical charts revealed that absence of symptomatic improvement often could be explained by dysfunctional stents, migrations, infections, pain, or intercurrent diseases during the first 2 weeks. This represented a limited number of patients and separate subanalyses were not performed. Furthermore, ongoing treatment with other modalities (e.g., chemotherapy) can potentially influence symptom scoring negatively. We found no significant difference in the scorings of the 25 patients who received chemo- and/or radiation therapy during the assessment period.

Our study did not identify subgroups of patients that regularly did not benefit from SEMS treatment and, therefore, should have received alternative palliative treatment. This might be due to the relatively low number of patients included.

Seventy-six patients completed only the first questionnaire. However, as shown in Fig. [1](#Fig1){ref-type="fig"}, only 27 patients failed to complete the second questionnaire for unknown reasons. It is possible that these patients did not experience the expected effect of the stent treatment and that this lack of data could represent a selection bias. However, we know that these 27 patients did not differ in age, pretreatment global health, or survival from the 162 repliers. Three of these 27 patients experienced dysfunctional stents and needed reinterventions during the first 2 weeks, which might have influenced their opinion of stent function. Three patients experienced cholangitis and/or pancreatitis immediately after biliary stenting but had functional stents. For the remaining 21 of the 27 patients, there was not sufficient information in their medical records to explain why they did not return their second questionnaire.

Conclusion {#Sec12}
==========

SEMS treatment is effective in relieving symptoms of malignant GI and biliary obstruction, according to assessment by both patients and physicians. This study demonstrates a significant difference in how the physicians and patients evaluate treatment effects and thereby the importance of taking patient-reported outcomes into account when evaluating clinical palliative interventions. Future studies evaluating SEMS treatment should include prospective assessment of patient-reported outcomes to increase our knowledge about the efficacy of this treatment.
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